Retinal Imaging Biomarkers and Endpoints Summit

1 year ago Posted By : User Ref No: WURUR139338 0
  • Image
  • TypeConference
  • Image
  • Location Boston, Massachusetts, United States
  • Price
  • Date 13-06-2023 - 15-06-2023
Retinal Imaging Biomarkers and Endpoints Summit, Boston, Massachusetts, United States
Conference Title
Retinal Imaging Biomarkers and Endpoints Summit
Event Type
Conference
Conference Date
13-06-2023 to 15-06-2023
Location
Boston, Massachusetts, United States
Organization Name / Organize By
Hanson Wade
Organizing/Related Departments
Hanson Wade
Organization Type
Event Organizing Company
ConferenceCategory
Non Technical
ConferenceLevel
All (State/Province/Region, National & International)
Related Industries

Research/Science

Location
Boston, Massachusetts, United States

Uniting biotech and pharma scientists to revolutionize ophthalmic drug development, the Retinal Imaging Biomarkers and Endpoints Summit encourages forward-thinking discussions to enhance the adoption of novel imaging-based approaches to determine retinal function and optimize development of regulatory accepted endpoints.

Join 60+ retinal imaging, innovation, R and D, preclinical and clinical experts from the likes of Genentech, AbbVie, Apellis, Janssen and Novartis to overcome the translational challenges of choosing and implementing novel ophthalmic imaging biomarkers and endpoints in your research, to accelerate earlier, non-invasive and personalised healthcare for ophthalmic and neurodegenerative patients.

Speakers: Sairam Bellum, Senior Principal Scientist, Merck, Daniel Chao, Senior Director - Translational, Experimental Medicine and Retina Clinical lead, Janssen, Victor Chong, Vice President and Global Head of Retina, Janssen, Tara DeSilva, Associate Professor, Cleveland Clinic, Kamal Dhakal, Eye Care Scientist, AbbVie, David Esposito, President and Chief Executive Officer, ONL Therapeutics, Simon Gao, Senior Scientist - Clinical Imaging, Genentech, Jing Hua, Medical Director, Boehringer Ingelheim, Ashwath Jayagopal, Chief Scientific Officer, Opus Genetics, Katie Litts, Scientist, Genentech, Mila Malhotra, Director - Medical and Clinical Development, REGENXBIO, Alex McKeown, Director - Translational Ophthalmology and Digital Programs Lead, Apellis, Samarendra Mohanty, Chief Scientific Officer, Nanoscope Therapeutics, Richard Nicholas, Professor of Practice Neurology, Imperial College London, Guillaume Normand, Director - Clinical Development, Novartis, David Esposito, President and Chief Executive Officer, ONL Therapeutics, Srinivas Sadda, President and Chief Scientific Officer, Doheny Eye Institute, Michael Tolentino, Co-Founder and Chief Scientific Officer, Aviceda Therapeutics, Paul Wille, Director - Product Development and Scientist, Abeona Therapeutics, Daniela Ferrara, Senior Director of Ophthalmology, Genentech, Khaled Nassar, Principal Expert Retinal Health, Principal Clinical Biomarker Lead, Boehringer Ingelheim

Others Details

URL:
Brochure: https://go.evvnt.com/1549947-3?pid=6581 

Registration Fees
Available
Registration Fees Details
Drug Developer Pricing - Conference + Workshop Day: USD 4297.00, Drug Developer Pricing - Conference Only: USD 2999.00, Standard Pricing - Conference + Workshop Day: USD 5297.00, Standard Pricing - Conference Only: USD 3799.00
Registration Ways
Website
Address/Venue
The Bostonian Boston  26 North Street  Pin/Zip Code : 02109
Contact
Clarice Handley

[email protected]

     (+1) 617 455 4188